Somoza Beatriz, Abderrahim Fatima, González José M, Conde M Victoria, Arribas Silvia M, Starcher Barry, Regadera Javier, Fernández-Alfonso María S, Díaz-Gil Juan J, González M Carmen
Departamento de Fisiología, Facultad de Medicina, C/Arzobispo Morcillo 2, 28029 Madrid, Spain.
Cardiovasc Res. 2006 Feb 15;69(3):764-71. doi: 10.1016/j.cardiores.2005.08.021. Epub 2005 Sep 29.
Liver growth factor (LGF), a mitogen for liver cells, reduces fibrosis in a rat model of cirrhosis. The present study assesses the possible vascular antifibrotic and antihypertensive effects of LGF treatment on spontaneously hypertensive rats (SHR).
Six-month-old male SHR and normotensive Wistar Kyoto rats (WKY) were treated with LGF (4.5 microg LGF/rat i.p. twice a week for 2 weeks). Haemodynamic parameters were measured in anaesthetized rats. Vascular structure and function were studied in carotid arteries using optical and confocal microscopy, radioimmunoassay for desmosine, and isometric tension recording.
LGF reduced systolic and diastolic blood pressure only in SHR. When compared to those of untreated SHR, carotid arteries from LGF-treated SHR showed: 1) a 50% reduction in collagen area and an increase in vascular smooth muscle cell number in the media, 2) no difference in total elastin content, but an increase in size of fenestrae in the internal elastic lamina, and 3) enhanced relaxation to acetylcholine, sodium nitroprusside, and forskolin. These effects were specific for SHR, since no changes were observed in LGF-treated WKY.
Short-term treatment with a low dose of LGF induced a large improvement in vascular structure and function and significantly reduced blood pressure in a rat model of essential hypertension. The present results could open future research to explore the vascular effects of this endogenous factor in order to determine its potential as an antifibrotic and antihypertensive agent in humans.
肝生长因子(LGF)是一种肝细胞促有丝分裂原,可减轻肝硬化大鼠模型中的纤维化。本研究评估LGF治疗对自发性高血压大鼠(SHR)可能的血管抗纤维化和降压作用。
6月龄雄性SHR和血压正常的Wistar Kyoto大鼠(WKY)接受LGF治疗(4.5微克LGF/大鼠,腹腔注射,每周两次,共2周)。在麻醉大鼠中测量血流动力学参数。使用光学显微镜和共聚焦显微镜、锁链素放射免疫测定法以及等长张力记录法研究颈动脉的血管结构和功能。
LGF仅降低SHR的收缩压和舒张压。与未治疗的SHR相比,接受LGF治疗的SHR的颈动脉表现为:1)胶原面积减少50%,中膜血管平滑肌细胞数量增加;2)总弹性蛋白含量无差异,但内弹性膜窗孔大小增加;3)对乙酰胆碱、硝普钠和福斯高林的舒张反应增强。这些作用对SHR具有特异性,因为在接受LGF治疗的WKY中未观察到变化。
低剂量LGF短期治疗可使原发性高血压大鼠模型的血管结构和功能有显著改善,并显著降低血压。目前的结果可能为未来研究探索这种内源性因子的血管作用打开大门,以确定其作为人类抗纤维化和降压药物的潜力。